Mainz Biomed N.V. Ordinary Shares - MYNZ STOCK NEWS

Mainz Biomed NV (NASDAQ:MYNZ), a molecular genetics diagnostic company, is launching several initiatives to raise awareness of colorectal cancer (CRC) detection in Germany. With around 73,000 new cases annually, CRC is a leading cause of cancer-related mortality, yet boasts a 90% survival rate when diagnosed early. The company is sponsoring the Gastro Update 2023 in Mainz and Berlin, and hosting a Patient Education Day in Mainz on March 11, 2023. Its flagship product, ColoAlert, offers non-invasive at-home CRC screening, aiming for better detection rates compared to traditional tests. Mainz Biomed is poised to expand further into the US market following FDA approval.

Mainz Biomed (NASDAQ:MYNZ) is organizing events in Germany for Colorectal Cancer Awareness Month this March. The aim is to raise awareness about the importance of early detection of colorectal cancer, which recorded over 1.9 million new cases globally in 2020. Hosting training sessions for healthcare professionals and an educational event for patients, Mainz Biomed emphasizes the efficacy of their at-home CRC detection kit, ColoAlert. CEO Guido Baechler stated the initiative targets reducing colorectal cancer statistics and improving early diagnosis.

Mainz Biomed N.V. announced that its CFO, Bill Caragol, will participate in a Virtual Fireside Chat with ClearThink IR on March 1, 2023, at 12 noon ET, via the Paltalk platform. The chat aims to inform potential investors about the company’s products and strategic growth initiatives. Mainz Biomed specializes in molecular genetic diagnostics for early cancer detection, primarily through its ColoAlert test for colorectal cancer (CRC), which is already CE-IVDR marked and available in several countries. The U.S. market opportunity for CRC screening is estimated at approximately $3.7 billion annually.

On February 21, 2023, Mainz Biomed (NASDAQ:MYNZ) announced it has executed option agreements to acquire the intellectual property portfolio for its ColoAlert product and novel mRNA biomarkers. This acquisition, done in collaboration with Uni Targeting Research AS and SOCPRA Sciences, aims to enhance the early detection capabilities of colorectal cancer (CRC). The full ownership of the IP is expected to streamline operations and lower costs for the company. Mainz is actively evaluating the mRNA biomarkers in two significant clinical studies, ColoFuture and eAArly DETECT, aiming for FDA approval to expand CRC screening options, potentially impacting their market share in a $3.7 billion opportunity.

Mainz Biomed, a molecular genetics diagnostic company, announced new partnerships with Marylebone Laboratory and Instituto de Microecologia to distribute its flagship product, ColoAlert, for colorectal cancer detection. This collaboration enables a broader commercialization of the at-home test across England and Spain, targeting a market of 26 million patients in Spain and 9 million in London. The company aims to enhance early detection of colorectal cancer, the second most lethal cancer in Europe, significantly improving survival rates. The test is CE-IVDR marked and already marketed in several EU countries, with plans for US regulatory approval.

Mainz Biomed (NASDAQ: MYNZ) has announced a new corporate health program in Germany for its colorectal cancer screening test, ColoAlert. This initiative aims to tap into the €1 billion annual market by integrating ColoAlert into BGM, a health network servicing 48 of Germany's largest companies. The program provides employees with easy access to colorectal cancer testing, addressing a critical health need as CRC is a leading cause of cancer-related deaths in Europe. The company's strategy includes launching an online portal for test registration and results communication, enhancing early detection and employee well-being.

Mainz Biomed N.V. (NASDAQ:MYNZ) released a corporate summary for the fiscal year 2022, highlighting significant advancements in cancer diagnostics. Key achievements include the initiation of pivotal studies such as the eAArly DETECT and ReconAAsense, aimed at enhancing colorectal cancer detection. The company expanded international partnerships, improved its leadership team, and secured a USD 25.8 million public offering. A focus on the development of ColoAlert and PancAlert reflects its commitment to advancing early detection methods, with results expected in 2023 for ongoing studies.

BERKELEY, Calif. and MAINZ, Germany, Dec. 20, 2022 - Mainz Biomed (NASDAQ:MYNZ) announced the enrollment of its first patient in the eAArly DETECT study, part of the ColoFuture initiative. This study evaluates novel mRNA biomarkers to enhance the ColoAlert test for colorectal cancer (CRC), targeting advanced adenomas. Enrollment is expected to conclude in Q1 2023, with results anticipated in 1H 2023. The study aims to improve diagnostic sensitivity and specificity, vital in CRC prevention. The company is also preparing for its U.S. pivotal study, ReconAAsense, set to begin in 2023.

Mainz Biomed has received approval for its pivotal study, ReconAAsense, aimed at evaluating the clinical performance of its colorectal cancer detection test. The study will enroll approximately 15,000 subjects across 150 sites in the U.S., with results expected in 2025. This study is crucial for obtaining FDA marketing authorization and enhancing the technical profile of Mainz Biomed's tests for detecting advanced adenomas, which can lead to colorectal cancer. The eAArly DETECT study aims to integrate novel biomarker technology to improve diagnostic sensitivity.